1074-63-1

Usage

Uses

Used in Pharmaceutical Industry:
3-(Cyclopentylamino)propionitrile is used as an intermediate in the synthesis of various drugs for its role in modifying biological activity and contributing to the development of new drug molecules and pharmaceuticals.
Used in Research and Development:
3-(Cyclopentylamino)propionitrile is used as a building block in the research and development of new therapeutic agents and drug formulations, playing a crucial role in the creation of innovative pharmaceutical products.
Used in Chemical Industry:
3-(Cyclopentylamino)propionitrile is utilized as an important chemical in the chemical industry for its versatility in the synthesis of a wide range of organic and medicinal compounds, enhancing the development of novel chemical entities.

InChI:InChI=1/C8H14N2/c9-6-3-7-10-8-4-1-2-5-8/h8,10H,1-5,7H2

Upstream product

• 107-13-1 acrylonitrile 
• 1003-03-8 Cyclopentamine 

Relevant academic research and scientific papers

Aza-Michael mono-addition using acidic alumina under solventless conditions

Aza-Michael reactions between primary aliphatic and aromatic amines and various Michael acceptors have been performed under environmentally-friendly solventless conditions using acidic alumina as a heterogeneous catalyst to selectively obtain the corresponding mono-adducts in high yields. Ethyl acrylate was the main acceptor used, although others such as acrylonitrile, methyl acrylate and acrylamide were also utilized successfully. Bi-functional amines also gave the mono-adducts in good to excellent yields. Such compounds can serve as intermediates for the synthesis of anti-cancer and antibiotic drugs.

CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS

The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, D, E, G, J, L, M, Q, a, and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD.

Carbazole-Containing Sulfonamides as Cryptochrome Modulators

The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, F, G, H, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, Cushing's syndrome, and glaucoma.

Synthesis and antiplatelet activity of new imidazole-4-carboxylic acid derivatives

1-Arylalkyl-5-phenylsulfonamino-imidazole-4-carboxylic acid esters and their carboxamides with an additional secondary amino group were synthesized and identified as antiplatelet agents in a low micromolar range (Born-test, inducer collagen). To describe the mechanism of action more precisely the Born-test was carried out as well with ADP, adrenaline or PAF, respectively. In addition, two compounds were investigated for their COX-1 inhibitory activities. Provided the essential structural criteria are met i.e. amide group or ester, sulfonylamino rest, hydrophobic moieties, and a secondary amino function, slight structural modifications are able to shift the pattern of activity among the above platelet receptors. So, the ester 5c exhibits PAF antagonistic activity at IC 50 = 1 μM and COX-1 inhibition (IC50 = 0.4 μM). The carboxamide 6c shows ADP antagonistic properties (IC50 = 2 μM). Compound 6g is as well PAF antagonistic (IC50 = 4 μM) and a COX-1 inhibitor (IC50 = 1 μM). The derivative 6i shows a strong antiadrenergic (IC50 = 0.15 μM) and PAF antagonistic (IC 50 = 0.66 μM) effect.

Sulfacytosine derivatives

N1 -(1,2-dihydro-2-oxo-4-pyrimidinyl)sulfanilamides, bearing a lower alkyl, cycloalkyl or cycloalkyl-lower alkyl substituent in the 1-position, prepared by reaction of the corresponding 1-substituted-1,2-dihydro-2-oxo-4-aminopyrimidine and N-acylated sulfanilyl chloride with subsequent hydrolysis, are described. The end products are useful as antibacterial agents.